Membership

The Working Group is a pathology-driven group of experts, assisted by experts clinicians, scientist and statisticians. The Working Group is open to open to include all pathologists willing to get involved in the activities of the group.

Please send an email to roberto@salgado.be

Information on Membership

    1. Membership of the Working Group is on a voluntary basis.
    2. All members will receive 2-3 times a year a mailing from the chair of the WG with the details of the ongoing projects so that all remain informed.
    3. This communication is done by e-mail and a copy of this mailing is posted on the BLOG of the TIL-website, under the item “Practical Info for all members”.
    4. In order to achieve uniformity in the methodology of scoring TILs worldwide, each member is encouraged to use the Internationally accepted guideline and do their part for promotion and dissemination of the guideline.

The following is a list of current members of the International Immuno-Oncology Working Group (TILs Working Group)*. A member is defined as a person willing to be involved, informed and be part of the activities of the TILs Working Group. The authors alone are responsible for the views expressed in the work of the TILs Working Group and they do not necessarily represent the decisions, policy or views of their employer.

  1. Roberto Salgado, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium (Co-Chair, Founder, Core-Group Member)
  2. Sherene Loi, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia (Co-Chair, Founder, Core-Group Member)
  3. Carsten Denkert, University of Marburg, Marburg, Germany (Co-Chair, Founder, Core-Group Member)
  4. Sunil Badve, Department of Pathology, Indiana University, Indianapolis, USA (Founder, Core-Group Member)
  5. Sandra Demaria, Department of Pathology, Weill-Cornell Medicine, New York, USA (Founder, Core-Group Member)
  6. Sylvia Adams, Perlmutter Cancer Center, New York University Medical School, New York, USA (Founder, Core-Group Member)
  7. Stefan Michiels, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France (Founder, Core-Group Member)
  8. David Rimm, Department of Pathology, Yale University School of Medicine, New Haven, USA (Core-Group Member)
  9. Fraser Symmans, Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, USA (Core-Group Member)
  10. Stephen Hewitt, Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, USA (Core-Group Member)
  11. John Bartlett, Ontario Institute for Cancer Research, Toronto, Canada; IGGM Edinburgh, UK (Core-Group Member)
  12. Torsten Nielsen, Genetic Pathology Evaluation Centre, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada (Core-Group Member)
  13. Christos Sotiriou, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium (Core-Group Member)
  14. Giuseppe Viale, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy (Core-Group Member)
  15. Giancarlo Pruneri, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico–Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy (Core-Group Member)
  16. Sybille Loibl, dlw Laborsoftware UG (haftungsbeschränkt) Lübben, Germany (Core-Group Member)
  17. Abaete Canto, Surgical Pathology, SBP
  18. Aicha Ben Taieb, Roche
  19. Aini Hyytiäinen, Department of Oral and Maxillofacial Diseases, Helsinki, Finland
  20. Akira I. Hida, Department of Pathology, Matsuyama Shimin Hospital, Ehime, Japan
  21. Akli Hanane – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  22. Alastair Thompson, Surgical Oncology, Baylor College of Medicine, Texas, USA
  23. Albrecht Stenzinger, Institute of Pathology Heidelberg (IPH), University Hospital Heidelberg, Heidelberg, Germany
  24. Alejandra Wernicke, Anatomical Pathology, Hospital Italiano de Buenos Aires, Argentina
  25. Alejandro Rojo-Sebastian – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  26. Aleksei Konstantinov, Department of Pathology, Saint-Petersburg clinical scientific and practical center for specialised types of medical care (oncological), St.Petersburg, Russia.
  27. Ales Ales, The Fingerland Department of Pathology, University Hospital Hradec Kralove, Czech Republic
  28. Alex Lefevre, Roche Diagnostics, Belgium
  29. Alex Decaluwe, Department of Radiology, Jules Bordet Institute, Belgium
  30. Alexander Emelyanov – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  31. Alexander Makanga, Histopathology Department, Betsi Cadwaladr University Health Board, United Kingdom
  32. Alexander J. Lazar, Departments of Pathology, Genomic Medicine, Dermatology, and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  33. Alfredo Butera – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  34. Alicia Iturriagagoitia – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  35. Allen Gown, PhenoPath Laboratories, Seattle, USA
  36. Amalika Edirisinghe, Pathology, NSW Health, Gosford, Australia
  37. Amanda Lowe, Visiopharm
  38. Amine Kallala, Hopitalle Charles Nicolle, Tunisia
  39. Amy Lo, Research Pathology, Genentech Inc., South San Francisco, USA        
  40. An Coosemans, Oncology, Laboratory of Tumor Immunology and Immunotherapy, KU Leuven, Belgium
  41. Ana Calatrava, Fundacion Intituto Valenciano de Oncologia, Valencia, Spain
  42. Ana Godoy – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  43. Ana Ramirez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  44. Ana C. Garrido Castro, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  45. Anant Madabhushi, Case Western Reserve University; Louis Stokes Cleveland Veterans Health Administration Medical Center, Ohio, USA
  46. Anders Dahlstrand – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  47. Andre Moreira, Pulmonary Pathology, New York University Center for Biospecimen Research and Development, New York University, New York, New York, USA
  48. Andrea Richardson, Department of Pathology, Johns Hopkins Hospital, Baltimore, USA
  49. Andrea Vingiani, Department of Pathology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
  50. Andreas Koulovasilopoulos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org United Kingdom
  51. Andrew Tutt, Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom
  52. Andrew H. Beck, PathAI, Inc., Cambridge, USA
  53. Andrew M. Bellizzi, Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, USA
  54. Angel Guerrero, Department of Oncology, IVO Valencia, Spain
  55. Angela Quintana, Vall d’Hebrón Hospital Research Institute, Autoimmune Diseases department, Barcelona, Spain
  56. Angela Thiel – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  57. Aniko Kovacs – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  58. Anita Cassiano – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  59. Anita Grigoriadis , Cancer Bioinformatics Lab, Cancer Centre at Guy’s Hospital, London, UK; School of Life Sciences and Medicine, King’s College London, London, United Kingdom
  60. Anna Ehinger, Department of Clinical Genetics and Pathology, Skåne University Hospital, Lund University, Lund, Sweden
  61. Anna Sapino, University of Turin / Candiolo Cancer Institute – FPO, IRCCS, Candiolo, Italy 
  62. Anne Martel, Medical Biophysics, University of Toronto, Toronto, Canada
  63. Anne Vincent-Salomon, Institut Curie, Department of Pathology, Inserm U934,Paris Sciences Lettres University, Paris, France
  64. Anne-Vibeke Laenkholm, Department of Surgical Pathology Zealand University Hospital, Demark
  65. Anthony Gill, University of Sydney, Sydney, Australia
  66. Antonio Wolff, Breast Cancer Trials, Women’s Malignancies Disease Group, The Johns Hopkins Kimmel Cancer Center, Baltimore, MD, USA
  67. Aparna Harbhajanka, Department of Pathology, University Hospitals Cleveland Medical Center affiliated  with Case Western University, Ohio, USA
  68. Arif Jahangir, Cancer Biology and Therapeutics Laboratory, School of Biomolecular and Biomedical Science, UCD Conway Institute, Dublin, Ireland
  69. Arman Rahman, Precision Oncology Ireland, Conway Institute, UCD Ireland
  70. Arthur Schreurs, Public Health and Primary Care, Katholieke Universiteit Leuven, Belgium
  71. Ashish Sharma, Department of Biomedical Informatics, Emory University, GA, USA
  72. Ashley Cimino-Mathews, Departments of Pathology and Oncology, The Johns Hopkins Hospital, Baltimore, USA               
  73. Ashok Srinivasan , National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA
  74. Asokan Paupathy, Department of Pathology, NSW Health Pathology, NSW Australia
  75. Ayushi Sahay, Pathology, Tata Memorial Centre, Mumbai, India
  76. Bai Baibai – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  77. Balazs Acs, Department of Pathology, Karolinska Institute, Sweden
  78. Baljit Singh, Department of Pathology, New York University Langone Medical Centre, New York, USA
  79. Beatriz Lopez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  80. Belma Dogdas – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  81. Benjamin Calhoun, Department of Pathology and Laboratory Medicine, UNC School of Medicine, USA
  82. Benjamin Haibe-Kans, Bioinformatics and Computational Genomics Laboratory, Princess Margaret Cancer Center, Toronto, Canada
  83. Benjamin Solomon, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  84. Bernadette McLaren – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  85. Bernardo L Rapoport, The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
  86. Bibhusal Thapa, Department of Medicine, University of Melbourne, Parkville, Australia
  87. Xiaoxian (Bill) Li, Emory University, USA
  88. Brad H. Nelson, Trev & Joyce Deeley Research Centre, British Columbia Cancer Agency, Victoria, Canada
  89. Brandon Gallas, Division of Imaging, Diagnostics, and Software Reliability, Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA
  90. Carla Valenti – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  91. Carlos Dos Anjo, Merck
  92. Carlos Castaneda, Department of Research, Instituto Nacional de Enfermedades Neoplásicas, Lima, Perú
  93. Carlos Hagen, Palex Medical SA – Exact Sciences Corp, Spain
  94. Carmen Ballesteros-Merino, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute/Providence Cancer Center, Portland, Oregon, USA
  95. Carmen Criscitiello, Department of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
  96. Carolien Boeckx, Roche Diagnostics, Belgium
  97. Carolien van Deurzen, Department of Pathology, Erasmus MC, Cancer Institute, Rotterdam, The Netherlands
  98. Caroline Carey,  Roche Diagnostics, Belgium
  99. Caterina Marchio, University of Turin at Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy 
  100. Cecile Colpaert, Department of Pathology, AZ Turnhout, Turnhout, Belgium
  101. Cecily Quinn, Department of Pathology, St Vincent’s University Hospital and University College Dublin, Dublin, Ireland
  102. Chakra S. Chennubhotla,  Department of Computational and Systems Biology, University of Pittsburgh, USA    
  103. Chanel Smart –  To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  104. Charles Parker, UCL Cancer Institute, United Kingdom
  105. Charles Swanton, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  106. Chau Huynh Giang, Pathology, Hung Vuong Hospital, Vietnam
  107. Cian Martyn – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  108. Cinzia Solinas, Azienda AUSL, Regional Hospital of Aosta, Aosta, Italy
  109. Clare Yu, Department of Physics and Astronomy, University of California, Irvine, Irvine, CA, USA
  110. Crispin Hiley, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  111. Cynthia Chauhan, Mayo Clinic Breast SPORE, Mayo Clinic, Rochester, MN, USA
  112. Damien Drubay, Gustave Roussy, Universite Paris-Saclay, Villejuif, France; Université Paris-Sud, Institut National de la Santé et de la Recherche Médicale, Villejuif, France
  113. Damilys Joelly Santos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  114. Daniel Bethmann, University Hospital Halle (Saale), Institute of Pathology, Halle (Saale), Germany    
  115. Daniel Stover, Ohio State University Comprehensive Cancer Center, Ohio, USA        
  116. Daniel Sur, Department of Medical Oncology, University of Medicine “I. Hatieganu” Cluj Napoca, Romania    
  117. Danny Jang – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org               
  118. David Clunie, Consulting, PixelMed, Pennsylvenia, USA
  119. David Williams, Anatomical Pathology, Austin Health, Heidelberg, Australia
  120. David A. Moore, Department of Pathology, UCL Cancer Institute, UCL, London, UK; University College Hospitals NHS Trust, London, United Kingdom
  121. Deborah A. Dillon, Department of Pathology, Brigham and Women’s Hospital, Boston, MA Department of Pathology, Dana Farber Cancer Institute, Boston, MA, USA
  122. Denis Larsimont, Department of Pathology, Jules Bordet Institute, Brussels, Belgium
  123. Dhanusha Sabanathan, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia
  124. Dhanvi Mathur, Life Sciences, Ahmedabad University, Gujarat, India
  125. Diana Ruiz – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  126. Dieter Peeters,  HistoGeneX NV, Antwerp, Belgium and AZ Sint-Maarten Hospital, Mechelen, Belgium
  127. Dimitrios Zardavas, Oncology Clinical Development, Bristol-Myers Squibb, Princeton, USA
  128. Dongyan Liu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  129. Dora Sabino – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  130. Doris Hoeflmayer, Institut für Pathologie , UK Hamburg, Germany
  131. Douglas B. Johnson, Department of Medicine, Vanderbilt University Medical Centre, Nashville, USA
  132. Duilio Della Libera – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  133. Aubrey Thompson, Department of Cancer Biology, Mayo Clinic, Jacksonville, USA
  134. Edgardo Parrilla Castellar, Q2 Solutions, USA
  135. Edi Brogi, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  136. Edith Perez, Department of Oncology, Mayo Clinic, Rochester, USA
  137. Eduardo Rrichardet, Instituto Oncológico Córdoba, Spain
  138. Ehab ElGabry, Roche, Tucson, USA
  139. Eiichi Konishi, Departments of Surgical Pathology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  140. Eiji Suzuki, Kyoto University, Department of Breast Surgery, Kyoto, Japan.
  141. El Attar Hicham  Biohisto Group, Annasr Pathology Center, Jedida, Morroco                 Morocco
  142. Eldad Klaiman, Roche
  143. Elena Provenzano, Department of histopathology, Addenbrookes Hospital, Cambridge University NHS Foundation Trust, Cambridge, United Kingdom
  144. Elisabeth Ida Specht Stovgaard, Department of Pathology, Herlev and Gentofte University Hospital, Herlev, Denmark
  145. Elizabeth F. Blackley, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  146. Elżbieta Senkus-Konefka, Department of Oncology & Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland
  147. Elton Rexhepaj, Research & Development, Sanofi
  148. Elvire Roblin, Université Paris-Saclay, Univ. Paris-Sud, Villejuif, France; and Service de biostatistique et d’épidémiologie, Gustave Roussy, Villejuif, France
  149. Emad Shash, Breast Cancer Comprehensive Center, National Cancer Institute, Cairo University, Cairo, Egypt
  150. Emarene Kalaw – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  151. Emiel Janssen, Department of Pathology, Stavanger University Hospital, Norway; Griffith University, Australia
  152. Emilio Bria, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy
  153. Emily Reisenbichler, Department of Pathology, Yale School of Medicine, New Haven, USA
  154. Emma Colliver – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  155. Enrico Orvieto, UOC Anatomia Patologica, ULSS5 Polesana Rovigo, Italy
  156. Enrique Bellolio, Department of Anatomic Pathology, Faculty of Medicine, Universidad De La Frontera, Temuco Chile     
  157. Erich Huang, National Cancer Institute, Maryland, USA
  158. Eslie Dennis, Ventana
  159. Eudald Felip, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
  160. Eunice Spengler, Departmento de Patologia, Hospital Universitario Austral, Argentina.
  161. Eva Balslev, Department of Pathology, Herlev and Gentofte Hospital, Denmark
  162. Ewa Chmielik, Tumor Pathology Department, Maria Sklodowska-Curie Memorial Cancer Center, Gliwice, Poland
  163. Ewan Millar, NSW Health Pathology, St George Hospital, Sydney, Australia
  164. Fabien Gaire, Pathology and Tissue Analytics, Roche
  165. Fabrice Andre, Department of Medical Oncology, Gustave Roussy, Villejuif, France
  166. Fang Fan, Department of Pathology, University of Kansas Medical Center, USA
  167. Fang-I Lu, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, Canada
  168. Farid Azmoudeh-Ardalan, Tehran University of Medical Sciences, Iran
  169. Fatima Cardoso, Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
  170. FayÇõal Abbad – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  171. Federica Miglietta, Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy
  172. Federico Rojo, Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  173. Felicia Leion – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  174. Felip Garcia, Pathology Department, Hospital Quiron Salud Spain
  175. Fernando Schmitt, Department of Pathology, Medical Faculty of Porto University, Porto, Portugal.
  176. Filipp Ofra – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  177. Filomena Carvalho – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  178. Fiorela Mego Ramirez –  To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  179. Fiorita Mundim – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  180. Francesco Ciompi, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
  181. Franciszek Binczyk – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  182. Franklin Peale, Oncology Biomarker Development, Genentech-Roche
  183. Franklin Sedarat, Q2 Solutions, USA
  184. Franz Burger – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  185. Fred R. Hirsch,    Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, USA
  186. Frederick Klaushen, Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany
  187. Frederique Penault-Llorca, Centre de Lutte Contre le cancer – Centre Jean Perrin, Clermont-Ferrand, France
  188. Gabor Cserni, Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary; Department of Pathology, University of Szeged, Szeged, Hungary.
  189. Gabriela Acosta-Haab, Department of Pathology, Hospital de Oncología Maria Curie, Buenos Aires, Argentina
  190. Gabriela IzabelaBaltatescu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  191. Galina Khramtsova – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  192. Gavin Harris, Canterbury Health Laboratories, New Zealand
  193. Gazzi Carla – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  194. GǬlcihan Eker – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  195. Gediminas Smailys – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  196. Gelareh Farshid, Directorate of Surgical Pathology, SA Pathology, Adelaide, Australia
  197. George Kumar,  Bristol Myers Squibb, USA
  198. Gert Van den Eynden, Department of Pathology, GZA-ZNA Ziekenhuizen, Wilrijk, Belgium
  199. Giampaolo Bianchini, Medical Oncology, San Raffael Scientific Institute, Italy
  200. Giampaolo Tortora – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  201. Giovanna Garufi, Medical Oncology Unit, Agistino Gemelli IRCCS Polyclinic Foundation, Rome, Italy.
  202. Giuseppe Floris, KU Leuven- Univerisity of Leuven, Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and KU Leuven- University Hospitals Leuven, Department of Pathology, Leuven, Belgium Belgium
  203. Giuseppe Curigliano, University of Milano, Istituto Europeo di Oncologia, IRCCS, Milano, Italy
  204. Gizem Oner, Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital Belgium
  205. Glenn Broeckx, Department of Pathology, University Hospital Antwerp, Belgium    
  206. Gloria Inurrigarro – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  207. Gun Min Kim – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  208. Guray Akturk, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  209. Gwen Dackus – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Netherlands
  210. Hannah Wen, Memorial Sloan Kettering Cancer Centre, USA
  211. Harmut Koeppen, Research Pathology, Genentech Inc., South San Francisco, USA
  212. Harry Haynes, Translational Health Sciences, Department of Cellular Pathology, North Bristol NHS Trust, University of Bristol, United Kingdom
  213. Heather McArthur, Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
  214. Heikki Joensuu, Helsinki University Central Hospital, Helsinki, Finland
  215. Helena Olofsson, Department of Clinical Pathology, Akademiska University Hospital, Uppsala, Sweden               
  216. Hernan Garcia Rivello, Anatomical Pathology, Hospital Italiano de Buenos Aires, Argentina.  
  217. Hirofumi Matsumoto, Department of Pathology, Nakagami Hospital, Okinawa, Japan
  218. Houssein Sater – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  219. Huang-Chun Lien, Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
  220. Hugo M. Horlings, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  221. Hyun Joo Choi, St. Vincent’s Hospital, The Catholic University of Korea, Seoul, South Korea
  222. Ian Cree, International Agency for Research on Cancer (IARC), World Health Organization, Lyon, France
  223. I-Chun Chen, Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan
  224. Ida Pavon, Ulss 3, Italy
  225. Ignasi Roig I Quilis, Departmento de Anatomia Patologica, Hospital de Terrassa, Barcelona, Spain
  226. Ilaria Porcellato, Department of Veterinary Medicine, University of Perugia, Italy
  227. Indu Arun, Department of Histopathology, Tata Medical Center, Kolkata, Indi
  228. Inna Ganshina – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  229. Inne Nauwelaers, Public Health and Primary Care, KU Leuven, Belgium
  230. Inta Liepniece- Karele – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  231. Ioannis Roxanis, Institute of Cancer Research, United Kingdom
  232. Ipek Coban, Anatomic Pathology, Istanbul Florence Nightingale Hospital, Turkey
  233. Iris Nederlof, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  234. Isaac Garcia-Murillas, Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom
  235. Isabel Amendoeira, Serviço de Anatomia Patológica, Centro Hospitalar Universitario de São João and Ipatimup, Porto, Portugal
  236. Isabel Frahm, Department of Pathology, Sanatorio Mater Dei, Buenos Aires, Argentina
  237. Isabella Castellano, Department of Medical Sciences, University of Turin, Italy
  238. Iva Brcic, Institute of Pathology, Medical University of Graz, Austria
  239. Jacinta Fong, Harry Perkins Institute of Medical Research, University of Western Australia
  240. Jack Chan, Department of Oncology, National Cancer Centre, Singapore
  241. Jacqueline A. Hall, Vivactiv Ltd, Bellingdon, Bucks, United Kingdom
  242. James Ziai, Research Pathology, Genentech Inc., South San Francisco, USA
  243. Jan Hudeek, Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  244. Jane Brock, Department of Pathology, Brigham and Women’s Hospital, Boston, USA
  245. Janina Kulka, Department of Pathology, Semmelweis University, Budapest, Hungary
  246. Javier Cortes, Head breast Cancer Program, Oncology Department, IOB institute of Oncology, Quiron Group, Spain
  247. Jean-Christophe Tille, Department of Pathology, University Hospital, Geneva, Switzerland
  248. Jeffrey Fine – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  249. Jeffrey Shear, Information Technology, Wiss & Company, LLP, J Shear Consulting, LLC, New York, USA               
  250. Jelle Wesseling,  Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands               
  251. Jennifer Giltnane, Research Pathology, Genentech Inc., South San Francisco, USA
  252. Jennifer Kerner, PathAI Inc., Cambridge, USA          
  253. Jeppe Thagaard, DTU Compute, Department of Applied Mathematics, Technical University of Denmark; Visiopharm A/S, Denmark
  254. Jeremy Braybrooke, Nuffield Department of Population Health, University of Oxford, Oxford and Department of Medical Oncology, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom
  255. Jeremy Thomas, Q2 Solutions, USA
  256. Jeroen Van der Laak, Computational Pathology Group, Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
  257. Jerome Lemonnier, R&D UNICANCER, Paris, France
  258. Jiping Zha, Translational Sciences, MedImmune, Gaithersberg, USA
  259. Joana Ribeiro, Breast Unit, Champalimaud Clinical Centre, Lisboa, Portugal
  260. Jochen K. Lennerz, Department of Pathology, Massachusetts General Hospital, Boston, MA, USA
  261. Jodi M. Carter, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
  262. Joel Saltz, Department of Biomedical Informatics and Department of Pathology, Stony Brook School of Medicine, Stony Brook, USA
  263. Joël Cucherousset, GHI Le Raincy-Montfermeil, Chelles, Île-de-France, France
  264. Johan Hartman, Deptartment of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
  265. Johan Lundin, Institute for Molecular Medicine Finland, University of Helsinki, Finland
  266. John Cochran, Q2 Solutions, Atlanta, GA, USA
  267. John Le Quesne, Leicester Cancer Research Centre, University of Leicester, Leicester, and MRC Toxicology Unit, University of Cambridge, United Kingdom
  268. Jonathan Klein, Albert Einstein College of Medicine in New York, USA
  269. Jonathon W. Juco, Merck & Co., Inc., Kenilworth, USA
  270. Jorge Reis-Filho, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  271. Jorge Adriano Ferreira Pinheiro – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  272. Jose van den Berg, Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  273. Jose Fernando do prado Moura, Centro de Pesquisas Clinicas do IMIP, Brasil
  274. Jose Ignacio Chacan – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  275. Jose Luis Solorzano Rendon, Pathology and Molecular Diagnostics department, MD Anderson Cancer Center Madrid, Spain
  276. Josefine Sandstrom, Linköping University, Sweden
  277. Joselyn Sanchez, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru
  278. Joseph Anderson – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  279. Joseph Sparano, Department of Medicine, Department of Obstetrics & Gynecology and Women’s Health, Albert Einstein Medical Center, Bronx, USA
  280. Juan Carlos Araya, Department of Pathology, Universidad de La Frontera, Temuco, Chile
  281. Julian Iturbe – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  282. Juliana Freitas, Pathology Department, Federal University of Bahia, Brazil
  283. Julien Adam, Department of Pathology, Gustave Roussy, Grand Paris, France
  284. Junjeong Choi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  285. Junzo Kawaguchi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  286. Justin M. Balko, Departments of Medicine and Cancer Biology, Vanderbilt University Medical Centre, Nashville, USA
  287. Kai Saeger,  Vm Scope, Germany
  288. Kareem Hosny, Department of Pathology, University of Pennsylvania, USA
  289. Karen Willard-Gallo, Molecular Immunology Unit, Institut Jules Bordet, Brussels, Belgium
  290. Karsten Weber, German Breast Group, Neu-Isenburg, Germany
  291. Karthickbalan Subramanian – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  292. Katey Enfield – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  293. Katherine Elfer, Division of Imaging, Diagnostics, and Software Reliability, US Food and Drug Administration, Silver Spring, MD, USA
  294. Katherine Pogue-Geile, NSABP/NRG Oncology, Pittsburgh, PA, USA
  295. KatsuhiroYoshikawa, Kansai Medical University Medical Center, Osaka, Japan
  296. Keith E. Steele, Translational Sciences, MedImmune, Gaithersberg, USA
  297. Kenneth Emancipator, Merck & Co., Inc., Kenilworth, USA
  298. Kevin Thia – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  299. Khalid El Bairi, Cancer Biomarkers Working Group, Oujda, Morocco
  300. Khalid Abdul Jabbar, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
  301. Kim R.M. Blenman, Department of Internal Medicine, Section of Medical Oncology, Yale Cancer Center, Yale University, School of Medicine, New Haven,  CT , USA
  302. Kimberly H. Allison, Pathology Department, Stanford University Medical Centre, Stanford, USA
  303. Koen K. van de Vijver, Department of Pathology, University Hospital Ghent, Belgium
  304. Konstanty (Popi) Korski, Data Science Imaging, Product Development – Personalized Healthcare, F.Hoffmann-La Roche Ltd., Basel, Switzerland
  305. Kosuke Kawaguchi, Department of Breast Surgery, Kyoto University, Kyoto, Japan.
  306. Kristin Galas – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  307. Lajos Pusztai, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale School of Medicine, New Haven, CT , USA
  308. Larissa Mendes, Oncology Department, Cancer Institute, University College London, London,                United Kingdom
  309. Laura Comerma, Pathology Department, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; GEICAM-Spanish Breast Cancer Research Group, Madrid, Spain
  310. Laura Yee, National Cancer Institute, Maryland, USA
  311. Laurence Buisseret, Molecular Immunology Unit, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  312. Lax Sigurd, Department of Pathology, Hospital Graz II, Academic Teaching Hospital of the Medical University Graz, Austria
  313. Lee Cooper, Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
  314. Leming Shi, Center for Pharmacogenomics and Fudan-Zhangjiang, Center for Clinical Genomics School of Life Sciences and Shanghai Cancer Center, Fudan University, China
  315. Leonie Voorwerk, Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  316. Leslie Cerpa – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  317. Leslie Gilham, Consumer Advisory Panel, Breast Cancer Trials, Australia
  318. Lingyu Li, School of Control Science and Engineering, Shandong University, China
  319. Lisa McShane, Cancer Therapy Evaluation Program, National Cancer Institute, Maryland, USA
  320. Liudmila Beziaeva – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  321. Loes Kooreman, Department of pathology, Maastricht University Medical Centre, Maastricht, The Netherlands
  322. LorenzoGianni -To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  323. Lounis Khaled – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  324. LubomirBodnar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  325. Luc Dirix, Medical Oncology, GZA, Antwerp, Belgium
  326. Luciana Fujimoto, Pathology and Legal Medicine, Amazon Federal University, Brasil
  327. Luciana Molinero, Oncology Biomarker Development, Genentech-Roche
  328. Luis Claudio, Amendola Brazilian Socity of Oncology, Brazil
  329. Luisa Paola, Molteni – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  330. Luz Sua, Department of Pathology, Fundación Valle del Lili, Cali, Colombia
  331. Valeria Estrada, Biorepository and Tissue Technology Shared Resources, University of California San Diego, USA
  332. Maartje van Seijen, Department of molecular pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
  333. Magali Lacroix-Triki, Department of Pathology, Gustave Roussy, Villejuif, France
  334. Maggie Cheang,  Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, United Kingdom
  335. Mahasti Saghatchian, Pathology, Institute Gustave Roussy, France
  336. Maise al Bakir, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, United Kingdom
  337. Makhlouf Ait Mouloud, Faculté de Médecine, Universite Mouloud MAMMERI, Algeria
  338. Mako Nogami – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  339. Manish Manu Subramaniam, Anatomic Pathology, Q2 Lab Solutions, United Kingdom
  340. Manu Sebastian, Departments of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  341. Maria Cebollero, Pathology Department. Hospital General Universitario Gregorio Marañón. Madrid, Spain.    
  342. Marcelo Balancin, Department of Pathology, Faculty of Medicine, University of São Paulo; São Paulo, Brazil
  343. Marcelo Souto Maior, Pathology, Federal University of Pernambuco, Brazil
  344. Maria Alice Franzoi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  345. Maria Pia Foschini – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  346. Maria Teresa Ramieri – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  347. Maria Vittoria Dieci – Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy
  348. Marie-Christine Mathieu – Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France
  349. Mariia Urezkova- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  350. Marilyn Bui – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  351. Marjan Hertoghs, Pathology department of ZNA and GZA hospitals in Antwerp, Belgium
  352. Mark Brown, Pathology, Q2 Solutions, United Kingdom
  353. Mark O’Loughlin- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  354. Mark Robson, Memorial Sloan Kettering Cancer Center, NY, US
  355. Mark Webber – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  356. Mark van de Vijver, Department of Pathology, Academic Medical Center, Amsterdam, The Netherlands
  357. Markus Herrmann – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org USA
  358. Marleen Kok, Divisions of Medical Oncology, Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  359. Marlon C. Rebelatto, Translational Sciences, MedImmune, Gaithersberg, USA
  360. Martine Piccart, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
  361. Martino Bosco, Pathology, ASLCN2, Italy
  362. Mary Schneck, Histogenex
  363. Masahiro Takada, Kyoto University, Department of Breast Surgery, Kyoto, Japan.
  364. Masakazu Toi, Department of Breast Surgery, Kyoto University, Kyoto, Japan.
  365. Masoumeh, Gharib, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  366. Matt Leavitt – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  367. Matthew G. Hanna, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  368. Matthew P. Goetz, Department of Oncology, Mayo Clinic, Rochester, USA
  369. Matthias Preusser, Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Vienna, Austria
  370. Mehrnoush Khojasteh, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA
  371. Melinda E. Sanders, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Centre, Nashville, USA
  372. Melisa Vazquez – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  373. Meredith M. Regan, Division of Biostatistics, Dana-Farber Cancer Institute, Boston, USA; Harvard Medical School, Boston, USA
  374. Michael Firer, Adelson School of Medicine, Ariel University, Israel
  375. Michael Barnes,Digital Pathology, Personalized Healthcare Group in Product Development, Genentech, USA
  376. Michael Christie, Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Australia
  377. Michael DiMaio, Pathology, DPMG, USA
  378. Michael Misialek , Vernon Cancer Center, Newton-Wellesley Hospital, Newton, USA
  379. Michail Sofopoulos, Department of Surgical Pathology, “Saint Savvas” Regional Anticancer Hospital, Athens Greece
  380. Michail Ignatiadis, Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  381. Michiel de Maaker, Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  382. Mieke Van Bockstal, Service de pathologique, Cliniques universitaires Saint-Luc, Bruxelles, Belgium
  383. MiglenaKomforti – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  384. Miluska Castillo, Department of Research, Instituto Nacional de Enfermedades Neoplasicas, Lima 15038, Peru
  385. Minetta Liu, Mayo Clinic, Rochester, Minnesota Joint Appointment, Department of laboratory Medicine and Pathology, Research Chair, Division of Medical Oncology, USA
  386. Mitsuaki Ishida, Department of Pathology and Laboratory Medicine, Kansai Medical University, Osaka, Japan
  387. Mohamed Zaakouk – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  388. Mohamed Amgad, Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA
  389. Mohamed Amgad Tageldin, Department of Biomedical Informatics, Emory University School of Medicine, Atlanta, GA, USA
  390. Molly Klein, Department of Laboratory Medicine and Pathology, University of Minnesota, USA
  391. Monica Modesto Araujo e Porfirio, Department of Pathology, Argos – Fortaleza-CE, Brazil
  392. Montse Velasco, Department of Oncology, Hospital de Mataro, Bercelona, Spain
  393. Morven Hollick, School of Medicine, Medical Science and Nutrition, University of Aberdeen, Scotland
  394. Nadia Villena – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  395. Nadia Harbeck, Breast Center, Dept. OB&GYN and CCC (LMU), University of Munich, Munich, Germany
  396. Nadine Tung,  Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, USA
  397. Naila Bacha – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  398. Najat Bouchmaa, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Beni Mellal, Morocco
  399. Nancy Samberg, Executive Director, Medical Affairs, Iovance Biotherapeutics, USA
  400. Navita Somaiah, Translational Breast Radiobiology, Institute of Cancer Research, Honorary Consultant Clinical Oncologist (Breast), The Royal Marsden, United Kingdom
  401. Nele Laudus, Biomedical Quality Assurance Research Unit, KU Leuven, Leuven, Belgium
  402. Nicolas Sirtaine, Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
  403. Nicole Bussola – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  404. Nicole Burchardi, German Breast Group GmbH, Germany
  405. Nikitina Vlada, Pathology, Krasnoyarsk State MEDICAL UNIVERSITY, Russia
  406. Nils Ternes, Service de Biostatistique et d’Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France
  407. Nina Radosevic-Robin, Department of Surgical Pathology and Biopathology, Jean Perrin Comprehensive Cancer Centre, Clermont-Ferrand, France
  408. Nobuhiro Shibata, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan
  409. NoriyukiSaito – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  410. Norie Abe, Breast Surgery, Nakagami Hospital, Okinawa, Japan
  411. Nuh Hatipoglu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  412. Ogugua Ajemba, Anatomic Pathology, Q2 Solutions, USA
  413. Oleg Gluz, Johanniter GmbH – Evangelisches Krankenhaus Bethesda Mönchengladbach, West German Study Group, Mönchengladbach, Germany
  414. Oliver Grimm, Pathology and Tissue Analytics, Roche
  415. Oluwole Fadare, Division of Anatomic Pathology, University of California San Diego Health System, USA
  416. Ovidiu Preda, Surgical Pathology, San Cecilio Hospital, Granada, Spain
  417. Paola Landini – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Argentina
  418. Paola Mercurio, Anatomic Pathology, ASST Bergamo Ovest, Italy
  419. Paola Migliora – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  420. Paolo Nuciforo, Molecular Oncology Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain
  421. Pascal Valerie – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  422. Patricia Lopez, Pathology, Instituto Nacional de Cancerologia, Colombia
  423. Paul Jank, Department of Pathology, University of Marburg, Marburg, Germany
  424. Paula Gonzalez Ericsson, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee , USA
  425. Paulo Figueiredo – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  426. Paulo Luz, Medical Oncology, Centro Hospitalar Universitario do Algarve, Faro, Portugal
  427. Pawan Kirtani, Department of Histopathology, Manipal Hospitals Dwarka, New Delhi, India
  428. Peggy Adam, Jules Bordet Institute, Belgium
  429. Petar Jelinic, Merck & Co., Inc., Kenilworth, USA
  430. Peter Regitnig – Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
  431. Peter Savas, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  432. Peter Vermeulen, Medical Oncology, GZA, Antwerp, Belgium
  433. Peter H. Watson, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
  434. Philippe Aftimos – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org Belgium
  435. Pia Waldenback – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  436. Pieter Westenend – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  437. Polina Dimitrova, Department of Pathology, University Hospital, Bulgary
  438. Pooja Vaid – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  439. Popi Siziopikou, Department of Pathology, Breast Pathology Section, Northwestern University, Chicago, USA
  440. PrayuthRojpornpradit – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  441. Perna Guleria, Army Hospital Research and Referral, Delhi Cantt, New Delhi, India
  442. Priyanka Sharma – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  443. Prudence A. Francis, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
  444. Raffaele Miele, ASL Napoli 1 Centro, Ospedale Pellegrini, Italy
  445. Raj Mohan, Command Hospital, India
  446. Rajendra Singh, Icahn School of Medicine at Mt. Sinai, New York, NY, USA
  447. RamonaErber – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  448. Rashi Gupta – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  449. Rashida Soni, Pathology, Q2 lab solutions and Henry Mayo Newhall Hospital, USA
  450. Rashindrie Perera, University of Melbourne, Australia
  451. Ravi Mehrotra – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  452. Rebecca Dent, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  453. Reena Merard, Anatomic Pathology, Q2 Lab Solutions, USA
  454. Reena Rahayu, Department of Pathology and Diagnostic Laboratory Services, UKM Medical Centre, Kuala Lumpur, Malaysia
  455. Reena Ramsaroop – Surgical Pathologist, North Shore Hospital, WDHB, Auckland, New Zealand
  456. Remi Picot – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org France
  457. Rena Feinman – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  458. Renan Andrade Pereira, Blazar SAS, Paris, France
  459. Ricardo Preda, Anatomical Pathology, NSW Health, Australia
  460. Richard Huang, Department of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA               
  461. Rick Baehner, Genomic Health
  462. Rin Yamaguchi, Department of Pathology & Laboratory Medicine, Kurume University Medical Center, Fukuoka, Japan.
  463. Robert Mutter, Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA
  464. robert wightman             To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  465. Robert Hills         Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford, UK                United Kingdom
  466. Robert H. Pierce     Cancer Immunotherapy Trials Network, Central Laboratory and Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, USA               USA
  467. Roberto Leon-Ferre Department of Oncology, Mayo Clinic, Rochester, USA          USA
  468. Rocco Cappellesso         Pathological Anatomy, Padova University Hospital Italy
  469. Roland de Wind Department of Pathology, Institut Jules Bordet, Brussels, Belgium    Belgium
  470. Ronald Luff, Anatomic Pathology for Clinical Trials, Quest Diagnostics, USA
  471. Rongshan Yu – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  472. Rosalia Caballero, GEICAM, Spain
  473. Ruben Cuesta – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  474. Ruohong Shui, Department of Pathology, Fudan University Cancer Center, China
  475. Sabine Declercq, Department of Pathology, GZA-ZNA Hospitals, Antwerp, Belgium
  476. Sabine Linn, Netherlands Cancer Institute, The Netherlands
  477. Saed Sadeghi – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  478. Sam Leung, University of British Columbia, Vancouver, British Columbia, Canada
  479. Sami Tabbarah, Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
  480. Samy Stefan, Teoran Pathology, SCJUPBT, Romania
  481. Sandra Sarancone – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  482. Sandra Souza, Oncology Merck & Co, New Jersey, USA
  483. Sandra O’Toole, The Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Australian Clinical Labs, Australia
  484. Sandra Swain, Georgetown University Medical Center, Washington DC, USA
  485. Sangeeta Desai, Pathology, Tata Memorial Centre, India
  486. Sara Bonetto, U.O. Anatomia Patologica, ASST Lariana-Ospedale “Sant’Anna di Como”, Italy
  487. Sarah Dudgeon, FDA/CDRH/OSEL/Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, USA
  488. Scooter Willis, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA
  489. Scott Ely, Translational Medicine, Bristol-Myers Squibb, Princeton, USA
  490. Sean Hall, The Gillies McIndoe Research Institute, Wellington, New Zealand
  491. Seher Yuksel – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  492. Seong-Rim Kim, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, USA
  493. Shahinaz Bedri, Anatomic Pathology, Boston, Massachusetts, USA
  494. Sheeba Irshad, Guy’s Hospital, London, UK; King’s College London, London, United Kingdom
  495. Shigehira Saji, Medical Oncology, Fukushima Medical University Hospital, Japan
  496. Shi-Wei Liu, Sichuan Cancer Hospital, Chengdu, China
  497. Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia
  498. Shona Hendry, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
  499. Shyam Kalavar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  500. Sidar Bagbudar – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  501. Simon Palfreeman – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  502. Simonetta Bianchi, Dipartimento di Scienze della Salute (DSS), Firenze, Italy
  503. Sneha Sant, Division of Research, Peter MacCallum Cancer Centre, Melbourne, Australia
  504. Sofia Tenorio – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  505. Soonmyung Paik, National Surgical Adjuvant Breast and Bowel Project Operations Center/NRG Oncology, Pittsburgh, Pennsylvania, USA
  506. Sophia Turner, Patient advocate
  507. Sophie Van den Broek – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  508. Stephan Wienert, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Pathology, Charitéplatz 1, 10117 Berlin, Germany
  509. Stephen Naber, Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, USA
  510. Stephen B. Fox, Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia
  511. Stephen J. Luen, Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia
  512. Steve Liu, Pathology, Washington University at St. Louis, USA
  513. Stuart Schnitt, Department of Pathology, Brigham and Women’s Hospital, Boston, MA; Dana-Farber Cancer Institute, Boston, MA, USA
  514. Sumana Dey, NCI
  515. Sundry DurÇ­n – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  516. Sunil R. Lakhani, The University of Queensland Centre for Clinical Research and Pathology Queensland, Brisbane, Australia
  517. Susan Fineberg, Department of Pathology, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, NY, USA
  518. Susan Park – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  519. Takahiro Kogawa, Japanese Foundation for Cancer Research, Tokyo, Japan
  520. Takashi Sakatani, Department of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan               
  521. Takeru Okamoto, Chugai Pharmaceutical Co., Ltd, Japan
  522. Takuya Moriya, Department of Pathology, Kawasaki Medical School, Okayama, Japan
  523. Talia Fuchs, NSW Health Pathology, Sydney, Australia
  524. Tatsuki Kataoka, Department of Diagnostic Pathology, Kyoto University, Kyoto, Japan.
  525. Tatsunori Shimoi , National Cancer Center Hospital, Tokyo, Japan
  526. Teresa Soler, Department of Pathology, University Hospital of Bellvitge, Oncobell, IDIBELL, L’Hospitalet del Llobregat, Barcelona 08908, Catalonia, Spain
  527. Tessa Steenbruggen, Medical Oncology, The Netherland Cancer Institute, The Netherlands
  528. Tetsuo Hamada, Department of Surgical Pathology, JR Kyushu Hospital, Kitakyushu, Fukuoka, Japan
  529. Thiago Apolinario, Department of Oncology, IMIP, Brazil
  530. Thomas Gevaert, Department of Development and Regeneration, Laboratory of Experimental Urology, KU Leuven, Leuven, Belgium
  531. Tim Mandelkow – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  532. Timothy d’Alfons, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
  533. Timothy Onyuma, Kenyatta National Hospital in Nairobi, Kenya.
  534. Tina Gruosso, Translational Research,  Forbius, Montreal, Canada
  535. Toby Ellis – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  536. Tom John, Department of Medical Oncology, Austin Health, Heidelberg, Australia
  537. Tomohagu Sugie, Department of Surgery, Kansai Medical School, Hirakata, Japan
  538. Tomoharu Sugie, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
  539. Tony Kwon – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  540. Toru Mukohara, National Cancer Center Hospital, Tokyo, Japan
  541. Tricia Saurine, Anatomical pathology, Royal North Shore Hospital, Australia
  542. Tsuyoshi Okamoto, Kyowa Kirin Co., Ltd, Japan
  543. Uday, Kurkure, Roche Tissue Diagnostics, Digital Pathology, Santa Clara, CA, USA
  544. Umay Kiraz, Pathology, Stavanger university hospital
  545. Valdivieso, Almeida – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  546. Valentina Hoyos- To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  547. Vasiliki Zolota – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  548. Veerle Bossuyt – Department of Pathology, Massachusetts General Hospital, USA
  549. Veronica Bautista, Department of Pathology, Breast Cancer Center FUCAM, Mexico City, Mexico
  550. Vijay Sharma, Pathology, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Trust, United Kingdom
  551. Vincent Cockenpot, Department of Pathology, Léon Bérard Cancer Center, Lyon, France
  552. Vincent Engelen – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  553. Vincent Laborie, Pathology, AMAPATH, France
  554. Vincente Peg, Cámaea Pathology Department, H.U. Vall d’Hebron, Barcelona, Spain
  555. Weida Tong, Division of Bioinformatics and Biostatistics, U.S. Food and Drug Administration, US
  556. Weijie Chen, Division of Imaging, Diagnostics, and Software Reliability (DIDSR), Office of Science and Engineering Laboratories (OSEL), Center for Devices and Radiological Health (CDRH), Rockville, USA
  557. Weijie Zhang – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  558. Wentao Yang, Department of Pathology, Fudan University Cancer Center, China
  559. Wenxian Yang, Aginome Scientific Pte Ltd., Xiamen, China
  560. Wilhermo Torres, Pathology, Diagnose, Brazil
  561. William Gallagher – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  562. William Tran, Department of Radiation Oncology, University of Toronto, Toronto, Canada     
  563. Yannick Waumans, Histogenex    
  564. Yara Abdou – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  565. Yazaki Shu, National Cancer Center Hospital, Tokyo, Japan
  566. Yihong Wang, Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Providence, USA
  567. Yinyin Yuan, Centre for Evolution and Cancer; Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom
  568. YongjunCha – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  569. Yuan Li – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  570. Yuchun Lin – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  571. Yuichiro Kikawa, Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
  572. Yuji Kozuka, Department of Pathology, Mie University School of Medicine, Mie, Japan
  573. Yuri Kimura – To be completed, please contact roberto@salgado.be and/or jeannette.parrodi@petermac.org
  574. Zaheed Husain, Praava Health, Dhaka, Bangladesh
  575. Zheng Yuan, Histogenex, China
  576. Zsuzsanna Bago-Horvath, Department of Pathology, Medical University of Vienna, Vienna, Austria
  577. Zuzana Kos, Department of Pathology, BC Cancer Agency Vancouver Centre, Department of Pathology, Canada
*Update in progress. Please email roberto@salgado.be for any changes.